Craft

TESARO

Revenue

$223.3 M

FY, 2017

TESARO Summary

Company Summary

Overview
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. It develops rolapitant, a potent, selective neurokinin-1 receptor antagonist that can be used for the prevention of chemotherapy-induced nausea and vomiting. The company advances its ALK inhibitor program for oncology indications.
Type
Subsidiary
Status
Closed
Founded
2010
HQ
Waltham, MA, US | view all locations
Website
http://www.tesarobio.com/
Cybersecurity rating
Sectors

Key People

  • Mary Lynne Hedley

    Mary Lynne Hedley, President, Chief Operating Officer

    • William Aitchison

      William Aitchison, Senior Vice President, Technical Operations

      • Greg Covino

        Greg Covino, Senior Vice President, Chief Accounting Officer

        • Allene Diaz

          Allene Diaz, Senior Vice President, Global Commercial Development and Program Strategy

          Operating MetricsView all

          Products

          2

          FY, 2016

          Countries

          7

          FY, 2016

          Patent Portfolios

          3

          FY, 2016

          LocationsView all

          8 locations detected

          • Waltham, MA HQ

            United States

            1000 Winter St

          • Wien, Wien

            Austria

            Fleischmarkt 1

          • Boulogne-Billancourt, Île-de-France

            France

            235 Avenue le Jour Se Lève

          • München, BY

            Germany

            Leopoldstraße 37a

          • Roma, Lazio

            Italy

            Via Vincenzo Bellini, 22

          • Madrid, Comunidad de Madrid

            Spain

            Camino de la Zarzuela, 19, 1ºC

          and 2 others

          TESARO Financials

          Summary Financials

          Revenue (Q3, 2018)
          $64.4M
          Gross profit (Q3, 2018)
          $50.2M
          Net income (Q3, 2018)
          ($137.1M)
          Cash (Q3, 2018)
          $476.8M
          EBIT (Q3, 2018)
          ($138.2M)

          Footer menu